Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast

Journal of Pathology

Volumn 232, Issue 5, 2014, Pages 553-565

  Natrajan, Rachael ^a   Wilkerson, Paul M ^a   Marchiò, Caterina ^b   Piscuoglio, Salvatore ^c   Ng, Charlotte K Y ^c   Wai, Patty ^a   Lambros, Maryou B ^a   Samartzis, Eleftherios P ^d   Dedes, Konstantin J ^d   Frankum, Jessica ^a   Bajrami, Ilirjana ^a   Kopec, Alicja ^a   Mackay, Alan ^a   A'Hern, Roger ^a   Fenwick, Kerry ^a   Kozarewa, Iwanka ^a   Hakas, Jarle ^a   Mitsopoulos, Costas ^a   Hardisson, David ^e   Lord, Christopher J ^a   Kumar Sinha, Chandan ^f   Ashworth, Alan ^a   Weigelt, Britta ^c   Sapino, Anna ^b   Chinnaiyan, Arul M ^f   Maher, Christopher A ^g   Reis Filho, Jorge S ^c   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; CDK12; fusion transcripts; micropapillary; PARP inhibitors; RNA sequencing; somatic mutation profiling

Indexed keywords

AURKA PROTEIN; BCAS4 PROTEIN; FAF1 PROTEIN; GLUCOSE TRANSPORTER 1; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA EXTRACTION; FUNCTIONAL ASSESSMENT; FUSION GENE; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; MICROPAPILLARY CARCINOMA; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RNA EXTRACTION; RNA SEQUENCE; SOMATIC MUTATION;

BREAST CANCER; CDK12; FUSION TRANSCRIPTS; MICROPAPILLARY; PARP INHIBITORS; RNA SEQUENCING; SOMATIC MUTATION PROFILING;

BREAST NEOPLASMS; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; SEQUENCE ANALYSIS, RNA; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84895929400     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4325     Document Type: Article

References (59)

1. Lakhani SR, Ellis IO, Schnitt SJ, et al., WHO Classification of Tumours of the Breast (4th edn). IARC Press: Lyon, 2012.
2. Marchio C, Iravani M, Natrajan R, et al., Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 2009; 218: 301-315.
3. Marchio C, Iravani M, Natrajan R, et al., Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008; 215: 398-410.
4. Weigelt B, Geyer FC, Reis-Filho JS,. Histological types of breast cancer: how special are they? Mol Oncol 2010; 4: 192-208.
5. Weigelt B, Reis-Filho JS,. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nature Rev Clin Oncol 2009; 6: 718-730.
6. Persson M, Andren Y, Mark J, et al., Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106: 18740-18744.
7. Tognon C, Knezevich SR, Huntsman D, et al., Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-376.
8. Bertucci F, Orsetti B, Negre V, et al., Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008; 27: 5359-5372.
9. Weigelt B, Geyer FC, Natrajan R, et al., The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010; 220: 45-57.
10. Ding L, Ellis MJ, Li S, et al., Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
11. Shah SP, Morin RD, Khattra J, et al., Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
12. Stephens PJ, McBride DJ, Lin ML, et al., Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
13. Edgren H, Murumagi A, Kangaspeska S, et al., Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 2011; 12: R6.
14. Natrajan R, Mackay A, Lambros MB, et al., A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J Pathol 2012; 227: 29-41.
15. Banerji S, Cibulskis K, Rangel-Escareno C, et al., Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486: 405-409.
16. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
17. Robinson DR, Kalyana-Sundaram S, Wu YM, et al., Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med 2011; 17: 1646-1651.
18. Ha KC, Lalonde E, Li L, et al., Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. BMC Med Genomics 2011; 4: 75.
19. Kalyana-Sundaram S, Shankar S, Deroo S, et al., Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia 2012; 14: 702-708.
20. Geyer FC, Weigelt B, Natrajan R, et al., Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010; 220: 562-573.
21. Marchio C, Natrajan R, Shiu KK, et al., The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008; 216: 399-407.
22. Hernandez L, Wilkerson PM, Lambros MB, et al., Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol 2012; 227: 42-52.
23. Coe BP, Ylstra B, Carvalho B, et al., Resolving the resolution of array CGH. Genomics 2007; 89: 647-653.
24. Gunnarsson R, Staaf J, Jansson M, et al., Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia-a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008; 47: 697-711.
25. Tan DS, Lambros MB, Natrajan R, et al., Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007; 87: 737-754.
26. Natrajan R, Weigelt B, Mackay A, et al., An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010; 121: 575-589.
27. Duprez R, Wilkerson PM, Lacroix-Triki M, et al., Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol 2012; 226: 427-441.
28. Wagle N, Berger MF, Davis MJ, et al., High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
29. De Mattos-Arruda L, Bidard FC, Won HH, et al., Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol 2013 (Epub ahead of print); DOI: 10.1016/j.molonc.2013.10.006.
30. DePristo MA, Banks E, Poplin R, et al., A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genet 2011; 43: 491-498.
31. Cibulskis K, Lawrence MS, Carter SL, et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol 2013; 31: 213-219.
32. Ding J, Bashashati A, Roth A, et al., Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics 2012; 28: 167-175.
33. McKenna A, Hanna M, Banks E, et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
34. Koboldt DC, Zhang Q, Larson DE, et al., VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
35. Robinson JT, Thorvaldsdottir H, Winckler W, et al., Integrative genomics viewer. Nature Biotechnol 2011; 29: 24-26.
36. Tanas MR, Sboner A, Oliveira AM, et al., Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011; 3: 98ra82.
37. Iyer MK, Chinnaiyan AM, Maher CA,. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011; 27: 2903-2904.
38. Wilkerson PM, Dedes KJ, Wetterskog D, et al., Functional characterization of EMSY gene amplification in human cancers. J Pathol 2011; 225: 29-42.
39. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al., PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75.
40. Horlings HM, Weigelt B, Anderson EM, et al., Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 2013; 142: 257-269.
41. Ellis MJ, Ding L, Shen D, et al., Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
42. Nik-Zainal S, Alexandrov LB, Wedge DC, et al., Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-993.
43. Shah SP, Roth A, Goya R, et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
44. Doublier S, Belisario DC, Polimeni M, et al., HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 2012; 12: 4.
45. Vasmatzis G, Johnson SH, Knudson RA, et al., Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012; 120: 2280-2289.
46. Mao X, Boyd LK, Yanez-Munoz RJ, et al., Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res 2011; 1: 604-617.
47. Shiu KK, Wetterskog D, Mackay A, et al., Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene 2013 (Epub ahead of print); DOI: 10.1038/onc.2012.625.
48. Blazek D, Kohoutek J, Bartholomeeusen K, et al., The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011; 25: 2158-2172.
49. Menges CW, Altomare DA, Testa JR,. FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell Cycle 2009; 8: 2528-2534.
50. Vader G, Lens SM,. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786: 60-72.
51. Zang ZJ, Ong CK, Cutcutache I, et al., Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2011; 71: 29-39.
52. Shah SP, Kobel M, Senz J, et al., Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360: 2719-2729.
53. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al., Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012; 226: 84-96.
54. Harvey JM, Clark GM, Osborne CK, et al., Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
55. Jacobs TW, Gown AM, Yaziji H, et al., Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-1987.
56. Mackay A, Tamber N, Fenwick K, et al., A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009; 118: 481-498.
57. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al., Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
58. Sathirapongsasuti JF, Lee H, Horst BA, et al., Exome sequencing-based copynumber variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 2011; 27: 2648-2654.
59. Brough R, Frankum JR, Sims D, et al., Functional viability profiles of breast cancer. Cancer Discov 2011; 1: 260-273.